Track C3: Shaping Healthcare: The Critical Impact of Pharmaceutical Supply Chains and Regulatory Excellence
Sunday, 28 September | 10:30–12:00 | Riverfront Ballroom (Level 2)
In this breakout session, hear from industry experts on key topics including harmonisation and international collaboration in new drug evaluation and SS 644: 2025 Guidelines for the Supply and Delivery of Medication. This will be followed by a multidisciplinary panel discussion examining the complex interplay between pharmaceutical tariffs, supply chain resilience, and the cost and accessibility of medications, highlighting practical strategies pharmacists can adopt to minimise disruptions and optimise patient care outcomes.
Presentations
Regulatory Reliance, Harmonisation, and International Collaboration in New Drug Evaluation by Dr Tse Siang KANG
Synopsis
• Bulleted text
SS 644: 2025 Guidelines for the Supply and Delivery of Medication by Corrinne Yong Koon TAN
This session provides an overview of the development of the Singapore Standard on Supply and Delivery of Medicines (SS 644) and highlights the key updates in SS 644’s latest revision. It will also briefly explain the rationale for these changes and their implications for the supply, delivery, and safe management of medicines in healthcare.
Panel Discussion: Balancing Trade and Pharmaceuticals Supply Chain: Local and Global Outlook moderated by Ms Vidhya SEGAR
Panelists:
• Mr Ti Hwei HOW
• Dr Tse Siang KANG
• Ms Hong Yee LIM
Speakers and Moderator
Dr Tse Siang KANG
Head of Regulatory Sciences
North, East, West Asia
Pfizer Pte Ltd
Singapore
Dr Tse Siang Kang is the Regulatory Affairs North, East, West Asia Cluster Lead at Pfizer, where he oversees regulatory operations across several Asian markets. With over 20 years of experience spanning academia, regulatory authority, and industry, Dr Kang brings a uniquely comprehensive perspective to regulatory strategy and policy development in Asia.
Dr Kang is a frequent speaker at regional conferences and has authored publications on regulatory innovation and landscape evolution in Asia. His work continues to influence regulatory harmonisation and capacity-building efforts across the region.
Corrinne Yong Koon TAN
Executive Secretary
Secretariat of Health Professional Boards
Singapore
Mr Ti Hwei HOW
Vice President
Oncology Business Unit
International Markets
AstraZeneca
Singapore
Mr Ti Hwei How leads strategy and operations for AstraZeneca’s oncology portfolio in emerging markets, with over 25 years of experience in pharmaceuticals and consumer goods. He is passionate about transforming cancer care through ecosystem partnerships and health technology innovations. He also serves as a member of the Singapore Pharmacy Council, the National University of Singapore Pharmacy Programme Advisory Board, and the Ngee Ann Polytechnic Life Sciences and Chemical Technology Advisory Committee.
Ms Hong Yee LIM
Group Chief Pharmacist
National Healthcare Group
Director & Head
Pharmacy
Tan Tock Seng Hospital
Director for Centre for Allied Health and Pharmacy Excellence (CAPE)
President of the 119th Pharmaceutical Society of Singapore (PSS) Council
Singapore
Ms Hong Yee Lim is Group Chief Pharmacist of the National Healthcare Group (NHG) and Director and Head of the Pharmacy division of Tan Tock Seng Hospital (TTSH). She is also Director for Centre for Allied Health and Pharmacy Excellence, driving innovation among allied health and pharmacy professionals. Currently President of the 119th Pharmaceutical Society of Singapore (PSS) council, she has served on the council since 2018.
She holds an MBA (specialization in Healthcare Management) from the National University of Singapore School of Business and a Master in Community Pharmacy from Queens University Belfast. A registered hospital pharmacist with 25 years’ experience, she has strong interest in quality improvement, healthcare innovation, and leadership.
Ms Lim holds several portfolios across NHG and TTSH, including member of senior management, clinical boards, the Drugs and Therapeutics Committee, the Collaborative Prescribing Committee, and the TTSH Environmental, Social and Governance Committee. Her leadership tenure at TTSH has shaped her focus on drug supply chain resiliency and related strategic planning.
Ms Vidhya SEGAR
Market Access Manager
Singapore & Malaysia
Ipsen
Singapore
Ms Vidhya Segar’s career spans the full spectrum of healthcare, from frontline hospital care to national policy and industry strategy. She began her career in Singapore’s public hospitals, where she practiced in both inpatient and outpatient settings, led hospital-wide deprescribing initiatives, and designed structured training and leadership development programs for pre-registration and early-career pharmacists. While there, she also completed a self-funded master’s degree in Clinical Pharmacy. At the Ministry of Health, she led the national rollout of medical device subsidies, including the implant subsidy list, a major reform that expanded access through value-based coverage and price negotiations. Today, she leads market access for Singapore and Malaysia at a mid-sized pharmaceutical company, driving pricing and go-to-market strategies in oncology and rare diseases.
